Want to see ORGO full AI Analyst Report?
ORGO Stock Chart & Stats
$4.08
-$0.06(-1.89%)
At close: 4:00 PM EST
$4.08
-$0.06(-1.89%)
Day’s Range― - ―
52-Week Range$2.04 - $7.08
Previous CloseN/A
Volume97.61K
Average Volume (3M)752.95K
Market Cap
$337.13M
Enterprise Value$418.43
Total Cash (Recent Filing)$92.10M
Total Debt (Recent Filing)$70.86M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Aug 06, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding128,674,550
10 Day Avg. Volume795,581
30 Day Avg. Volume752,949
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)1.17
P/FCF Ratio-26.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$3.00Price Target Upside-26.47% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.82
Revenue Forecast (FY)$282.87M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~69% gross margin indicates durable product economics for biologic and tissue products. Strong gross margin provides cushion to absorb volume shocks, supports gross-profit driven reinvestment in R&D and commercialization, and underpins long-term margin recovery as utilization normalizes.
Manageable Leverage And LiquidityMaterial deleveraging and modest leverage give the company financial flexibility to fund operations and regulatory programs without heavy interest burden. A stronger balance sheet supports working-capital needs, access to revolver capacity, and resilience during a multi-quarter recovery.
Regulatory Milestone: BLA SubmissionA completed BLA for ReNu represents a structural growth catalyst into a large nonsurgical knee OA market. If approved, it diversifies revenue beyond wound care, expands addressable market, and creates longer-term upside that is less tied to wound reimbursement cycles.
Bears Say
Sharp Revenue Guidance CutA materially reduced 2026 revenue outlook implies a sustained loss of scale and pricing leverage. Large volume declines compress operating leverage, hinder fixed-cost absorption, and limit the company's ability to sustain commercialization and R&D investments until volumes recover.
CMS-related Utilization DisruptionPolicy-driven clinician confusion and reimbursement uncertainty represent structural demand risk for wound-care products. Prolonged CMS or payer ambiguity can suppress utilization for months, undermining predictable revenue and complicating forecasting and commercial incentives.
Inventory Write-downs And Margin VolatilityLarge inventory and regulatory charges signal execution and forecasting weaknesses; such write-downs reduce earnings quality and indicate risk of recurring obsolescence or reimbursement reversals. Margin volatility makes sustainable operating profitability harder to achieve.
Organogenesis Holdings News
ORGO FAQ
What was Organogenesis Holdings’s price range in the past 12 months?
Organogenesis Holdings lowest stock price was $2.04 and its highest was $7.08 in the past 12 months.
What is Organogenesis Holdings’s market cap?
Organogenesis Holdings’s market cap is $337.13M.
When is Organogenesis Holdings’s upcoming earnings report date?
Organogenesis Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Organogenesis Holdings’s earnings last quarter?
Organogenesis Holdings released its earnings results on May 07, 2026. The company reported -$0.366 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.076.
Is Organogenesis Holdings overvalued?
According to Wall Street analysts Organogenesis Holdings’s price is currently Overvalued.
Does Organogenesis Holdings pay dividends?
Organogenesis Holdings does not currently pay dividends.
What is Organogenesis Holdings’s EPS estimate?
Organogenesis Holdings’s EPS estimate is -0.35.
How many shares outstanding does Organogenesis Holdings have?
Organogenesis Holdings has 128,674,550 shares outstanding.
What happened to Organogenesis Holdings’s price movement after its last earnings report?
Organogenesis Holdings reported an EPS of -$0.366 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -6.324%.
Which hedge fund is a major shareholder of Organogenesis Holdings?
Currently, no hedge funds are holding shares in ORGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organogenesis Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (-26.47% Downside)
$3.00 (-26.47% Downside)
Blogger Sentiment
Bullish
ORGO Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 18.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.25%
Trailing 12-Months
Company Description
Organogenesis Holdings
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
ORGO Stock 12 Month Forecast
Average Price Target
$3.00
▼(-26.47% Downside)
Technical Analysis
Ownership Overview
17.00% Insiders
7.01% Mutual Funds
1.69% Other Institutional Investors
62.55% Public Companies and
Individual Investors